Prostate cancer
CDZR123A12107
A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer.
Trial overview
Clinical Area
Medical Oncology
Disease
Prostate
Disease site
Genitourinary (GU)
Study Phase
Phase I
Trial Identifiers
Registration number: NCT07206056
GenesisCare Location(s)
Principal Investigator(s)
Clinical trials enquiries